Nephrology and Dialysis Unit, CTO Hospital, Turin, Italy.
J Nephrol. 2011 Mar-Apr;24(2):165-76. doi: 10.5301/jn.2010.2380.
Few reports have addressed how current practice reflects uncertainty as to the optimal management of renal replacement therapy (RRT) in Western countries. Current dialytic practice for 2007 in the northwest of Italy was assessed.
A total of 24 nephrology and dialysis centers covering all of the RRT provided in the intensive care units (ICUs) in northwest Italy took part in the survey. Consultant nephrologists of each center reported their own activities throughout the year 2007 by an e-mailed questionnaire.
RRT for a total of 7,842 days was provided by 24 dialysis centers in 79 ICUs for 1,118 patients. RRT median duration (5.76 days/patient) increased with the increasing number of hospital ICU beds. Of the RRT cases, 69.9% were due to acute kidney injury, 23.6% for continuation of a treatment in chronic dialysis patients and 4.2% for extrarenal indications. More than 90% of the patients were treated with high permeability membranes, at a median target dosage of 35.0 ml/kg per hour in continuous (39.4%) or extended modality (6-14 hours, 38.5%). Unfractionated heparin was the most common anticoagulant used (67.5%, median 500 IU/hour). In patients at high risk of bleeding, RRT without or with heparin at low-dose + saline flushes was the most commonly adopted line of treatment, followed by citrate (18% of days of dialysis). The decision to start RRT was made by nephrologists alone or in collaboration with intensivists, whereas dose prescriptions were given by nephrologists alone.
This survey may represent a useful starting point for further research into changes in RRT practice and the adoption of common, shared protocols.
目前,很少有研究报告涉及西方国家在肾脏替代治疗(RRT)的最佳管理方面的实践不确定性。评估了意大利西北部 2007 年当前的透析实践。
共有 24 个肾病和透析中心涵盖了意大利西北部所有 ICU 中提供的 RRT,参与了这项调查。每个中心的顾问肾病学家通过电子邮件问卷报告了他们自己在 2007 年全年的活动。
24 个透析中心在 79 个 ICU 中为 1118 名患者提供了总计 7842 天的 RRT。RRT 的中位持续时间(每位患者 5.76 天)随 ICU 病床数量的增加而增加。在 RRT 病例中,69.9%是由于急性肾损伤,23.6%是为了继续慢性透析患者的治疗,4.2%是由于肾外原因。超过 90%的患者接受高通透性膜治疗,在连续(39.4%)或扩展模式(6-14 小时,38.5%)中中位目标剂量为 35.0 ml/kg/小时。最常用的抗凝剂是未分级肝素(67.5%,中位 500 IU/小时)。在有高出血风险的患者中,最常采用的治疗方法是无肝素或低剂量肝素+生理盐水冲洗,其次是柠檬酸盐(占透析天数的 18%)。开始 RRT 的决定是由肾病学家单独或与重症监护医生共同做出的,而剂量处方则由肾病学家单独制定。
这项调查可能是进一步研究 RRT 实践变化和采用共同、共享方案的有用起点。